Kerry Townsend1, Tess Petersen, Lori A Gordon, Anita Kohli, Amy Nelson, Cassie Seamon, Chloe Gross, Lydia Tang, Anu Osinusi, Michael A Polis, Henry Masur, Shyam Kottilil. 1. aLaboratory of ImmunoregulationbCritical Care Medicine Department, National Institutes of Health Clinical CentercClinical Center Pharmacy Department, National Institutes of Health, Bethesda, MarylanddCollege of Pharmacy, Xavier University of Louisiana, New Orleans, LouisianaeClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc), Frederick National Laboratory for Cancer Research, Frederick, MarylandfDivision of Hepatology, St. Josephs Hospital and Medical Center, Creighton University Medical School, Phoenix, ArizonagDivision of Infectious Diseases, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MarylandhGilead Sciences Inc., Foster City, California, USA.
Abstract
OBJECTIVE: As the treatment of hepatitis C virus (HCV) infection has evolved to directly acting antiviral agents, the impact of these directly acting antiviral-only regimens on improving adherence to HCV treatment in HIV/HCV coinfected populations has not been evaluated. The study compared adherence to ledipasvir/sofosbuvir (LDV/SOF) in HCV monoinfected and HIV/HCV coinfected individuals. DESIGN: Adherence was measured from participants in two phase 2 open-label studies (NCT01805882 and NCT01878799). METHODS: HCV treatment-naive, genotype 1 study individuals [HCV monoinfected participants (N = 20) and HIV/HCV coinfected participants, antiretroviral untreated (N = 13) or on combination antiretroviral therapy (N = 37)] were treated with LDV (90 mg) and SOF (400 mg) administered as one tablet once daily for 12 weeks. Adherence was measured using three tools: medication event monitoring system cap, pill count, and patient report. RESULTS: Participants were predominately African American (83%) and male (73%), with a median age of 59 years. Participants had prompt HCV viral load decline and high adherence rates (97 ± 0.5% by medication event monitoring system). Participant adherence decreased significantly from early (baseline week 4) as compared with late (weeks 8-12) in therapy in all three groups - HCV monoinfected (P = 0.01), HIV/HCV antiretroviral untreated (P = 0.02), and HIV/HCV antiretroviral treated participants (P = 0.01). CONCLUSION: Adherence to LDV/SOF in this urban population was high and comparable between HCV monoinfected and HIV/HCV coinfected participants regardless of antiretroviral use.
OBJECTIVE: As the treatment of hepatitis C virus (HCV) infection has evolved to directly acting antiviral agents, the impact of these directly acting antiviral-only regimens on improving adherence to HCV treatment in HIV/HCV coinfected populations has not been evaluated. The study compared adherence to ledipasvir/sofosbuvir (LDV/SOF) in HCV monoinfected and HIV/HCV coinfected individuals. DESIGN: Adherence was measured from participants in two phase 2 open-label studies (NCT01805882 and NCT01878799). METHODS:HCV treatment-naive, genotype 1 study individuals [HCV monoinfected participants (N = 20) and HIV/HCV coinfectedparticipants, antiretroviral untreated (N = 13) or on combination antiretroviral therapy (N = 37)] were treated with LDV (90 mg) and SOF (400 mg) administered as one tablet once daily for 12 weeks. Adherence was measured using three tools: medication event monitoring system cap, pill count, and patient report. RESULTS:Participants were predominately African American (83%) and male (73%), with a median age of 59 years. Participants had prompt HCV viral load decline and high adherence rates (97 ± 0.5% by medication event monitoring system). Participant adherence decreased significantly from early (baseline week 4) as compared with late (weeks 8-12) in therapy in all three groups - HCV monoinfected (P = 0.01), HIV/HCV antiretroviral untreated (P = 0.02), and HIV/HCV antiretroviral treated participants (P = 0.01). CONCLUSION: Adherence to LDV/SOF in this urban population was high and comparable between HCV monoinfected and HIV/HCV coinfectedparticipants regardless of antiretroviral use.
Authors: Jesse Powell; Margaret Ricco; Jessica Naugle; Catherine Magee; Hayat Hassan; Carmen Masson; Grace Braimoh; Barry Zevin; Mandana Khalili Journal: Open Forum Infect Dis Date: 2021-09-25 Impact factor: 3.835
Authors: Meredith E Clement; Lauren F Collins; Julius M Wilder; Michael Mugavero; Taryn Barker; Susanna Naggie Journal: Infect Dis Clin North Am Date: 2018-06 Impact factor: 5.982
Authors: Jacqueline A Richmond; Suzanne Sheppard-Law; Susan Mason; Sherryne L Warner Journal: Patient Prefer Adherence Date: 2016-12-13 Impact factor: 2.711
Authors: Jürgen K Rockstroh; Karine Lacombe; Rolando M Viani; Chloe Orkin; David Wyles; Anne F Luetkemeyer; Ruth Soto-Malave; Robert Flisiak; Sanjay Bhagani; Kenneth E Sherman; Tatiana Shimonova; Peter Ruane; Joseph Sasadeusz; Jihad Slim; Zhenzhen Zhang; Suvajit Samanta; Teresa I Ng; Abhishek Gulati; Matthew P Kosloski; Nancy S Shulman; Roger Trinh; Mark Sulkowski Journal: Clin Infect Dis Date: 2018-09-14 Impact factor: 9.079
Authors: Sonia Vibhakar Patel; Dushyantha T Jayaweera; Keri N Althoff; Joseph J Eron; Janna Radtchenko; Anthony Mills; Graeme Moyle; Steven Santiago; Paul E Sax; Jason Gillman; Karam Mounzer; Richard A Elion; Gregory D Huhn Journal: PLoS One Date: 2020-02-13 Impact factor: 3.240